IRIS
POROTTO, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.160
AS - Asia 2.145
NA - Nord America 2.028
SA - Sud America 493
AF - Africa 34
OC - Oceania 1
Totale 8.861
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.043
US - Stati Uniti d'America 1.993
SG - Singapore 891
IE - Irlanda 546
BR - Brasile 425
CN - Cina 382
HK - Hong Kong 301
KR - Corea 220
VN - Vietnam 212
GB - Regno Unito 171
UA - Ucraina 125
IT - Italia 85
GR - Grecia 58
DE - Germania 54
AR - Argentina 35
IN - India 35
BD - Bangladesh 24
FR - Francia 17
CA - Canada 14
ID - Indonesia 14
EC - Ecuador 12
FI - Finlandia 12
IQ - Iraq 11
ZA - Sudafrica 11
MX - Messico 10
JP - Giappone 9
SA - Arabia Saudita 8
UZ - Uzbekistan 8
TR - Turchia 7
AT - Austria 6
CO - Colombia 6
MA - Marocco 6
NL - Olanda 6
CZ - Repubblica Ceca 5
EG - Egitto 5
ES - Italia 5
PL - Polonia 5
PY - Paraguay 5
TN - Tunisia 5
CL - Cile 4
PK - Pakistan 4
SE - Svezia 4
AL - Albania 3
BE - Belgio 3
BY - Bielorussia 3
JO - Giordania 3
KE - Kenya 3
KG - Kirghizistan 3
VE - Venezuela 3
CR - Costa Rica 2
GT - Guatemala 2
HN - Honduras 2
LK - Sri Lanka 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
UY - Uruguay 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KW - Kuwait 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
MV - Maldive 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 8.861
Salva come PNG Salva come JPEG
Città #
Moscow 1.162
Dublin 519
Santa Clara 379
Singapore 367
San Jose 329
Hong Kong 300
Jacksonville 234
Seoul 220
Chandler 96
New York 93
Princeton 76
Roxbury 76
Ho Chi Minh City 73
Ashburn 65
Medford 63
Beijing 59
Hanoi 51
Hefei 41
São Paulo 41
Des Moines 33
Menlo Park 32
Jinan 21
Wilmington 21
Munich 20
The Dalles 20
Nanjing 19
Cambridge 18
Dallas 18
Rio de Janeiro 17
Shenyang 16
Bengaluru 15
Los Angeles 14
Redwood City 14
Cagliari 12
Orem 12
Naples 11
Belo Horizonte 10
Caserta 10
Norwalk 10
Nuremberg 10
Tianjin 10
Curitiba 9
Rome 9
Atlanta 8
Brasília 8
Da Nang 8
Fairfield 8
Haiphong 8
Quito 8
Turku 8
Boardman 7
Hebei 7
Montreal 7
Mountain View 7
Ningbo 7
Tashkent 7
Biên Hòa 6
Boston 6
Bremen 6
Caxias do Sul 6
Guangzhou 6
Haikou 6
Hangzhou 6
Porto Alegre 6
Redmond 6
San Francisco 6
Zhengzhou 6
Ann Arbor 5
Changsha 5
Falkenstein 5
Juiz de Fora 5
Lanzhou 5
Taiyuan 5
Taizhou 5
Tokyo 5
Avellino 4
Baghdad 4
Campinas 4
Columbus 4
Dhaka 4
Goiânia 4
Guarulhos 4
Hải Dương 4
Johannesburg 4
Manchester 4
Mexico City 4
Milan 4
Nanchang 4
Quận Một 4
Riyadh 4
Salvador 4
Shanghai 4
São Gonçalo 4
Thái Bình 4
Vienna 4
Warsaw 4
Woodbridge 4
Amman 3
Anápolis 3
Bauru 3
Totale 4.926
Salva come PNG Salva come JPEG
Nome #
Analysis of a subacute sclerosing panencephalitis (SSPE) Genotype B3 virus from the 2009/10 South African measles epidemic shows hyperfusogenic F proteins contribute to measles virus infection in the brain 175
Human parainfluenza virus evolution during lung infection of immunocompromised humans promotes viral persistence 152
Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane 151
A rapid high-throughput assay for the identification of neutralizing antibodies and antiviral molecules against SARS-CoV-2 virus 151
Measles virus bearing MIBE-derived fusion protein is pathogenic after infection via the respiratory route 145
Effects of single α-to-β residue replacements on recognition of an extended segment in a viral fusion protein 141
Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection 133
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum 133
Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus 130
Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides 127
A broad-spectrum antiviral targeting entry of enveloped viruses 126
Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent 125
A three-dimensional model of human lung development and disease from pluripotent stem cells 124
A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity 122
A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism 117
Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue 116
Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro 115
Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals 113
Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length 110
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo 109
A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity 108
Biophysical properties and antiviral activities of measles fusion protein derived peptide conjugated with 25-hydroxycholesterol 108
Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus 108
Antiviral activity of nitazoxanide against Morbillivirus infections 107
Electron tomography imaging of surface glycoproteins on human parainfluenza virus 3: association of receptor binding and fusion proteins before receptor engagement 107
A neutralizing antibody prevents postfusion transition of measles virus fusion protein 105
Authentic modeling of human respiratory virus infection in human pluripotent stem cell-derived lung organoids 103
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia 102
Molecular determinants of antiviral potency of paramyxovirus entry inhibitors 100
Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus 100
Fatal measles virus infection prevented by brain-penetrant fusion inhibitors 98
The pH-sensitive action of cholesterol-conjugated peptide inhibitors of influenza virus 97
Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection 94
Fusion promotion by a paramyxovirus hemagglutinin-neuraminidase protein: pH modulation of receptor avidity of binding sites I and II 93
Viral entry properties required for fitness in humans are lost through rapid genomic change during viral isolation 92
Fusion inhibitory lipopeptides engineered for prophylaxis of nipah virus in primates 92
Molecular Features of the Measles Virus Viral Fusion Complex That Favor Infection and Spread in the Brain 92
Identification of a region in the stalk domain of the Nipah virus receptor binding protein that is critical for fusion activation 90
Paramyxovirus receptor-binding molecules: Engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site 90
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets 90
Absence of COVID-19-associated changes in plasma coagulation proteins and pulmonary thrombosis in the ferret model 88
Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides 88
Inhibition of parainfluenza virus type 3 and newcastle disease virus hemagglutinin-neuraminidase receptor binding: Effect of receptor avidity and steric hindrance at the inhibitor binding sites 87
Measles fusion machinery is dysregulated in neuropathogenic variants 87
Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles 87
Characterization of a SARS-CoV-2 Omicron BA.5 direct-contact transmission model in hamsters 86
Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment 86
Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism 86
Spring-loaded model revisited: Paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein 85
Viral entry inhibitors targeted to the membrane site of action 84
The in vitro multilineage differentiation and maturation of lung and airway cells from human pluripotent stem cell-derived lung progenitors in 3D 84
Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection 83
Design and evaluation of neutralizing and fusion inhibitory peptides to Crimean-Congo hemorrhagic fever virus 83
Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo 83
Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein 83
In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence 83
Features of circulating parainfluenza virus required for growth in human airway 83
Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy 83
Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the Fusion Protein 83
SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19 82
Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance 81
Human parainfluenza virus infection of the airway epithelium: Viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity 81
Mechanism of fusion triggering by human parainfluenza virus type III: Communication between viral glycoproteins during entry 81
Mechanism of interference mediated by human parainfluenza virus type 3 infection 80
Human parainfluenza virus type 3 HN-receptor interaction: Effect of 4-guanidino-neu5Ac2en on a neuraminidase-deficient variant 80
Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the sars-cov-2 spike glycoprotein hrc domain 80
Intermediates in SARS-CoV-2 spike-mediated cell entry 79
Inhibition of Hendra virus fusion 79
Measles virus fusion machinery activated by sialic acid binding globular domain 78
Hijacking the fusion complex of human parainfluenza virus as an antiviral strategy 78
Negative staining of proteins in polyacrylamide gels with methyl trichloroacetate 77
Kinetic dependence of paramyxovirus entry inhibition 77
The second receptor binding site of the globular head of the newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion 77
Triggering of human parainfluenza virus 3 fusion protein (F) by the hemagglutinin-neuraminidase (HN) protein: an HN mutation diminishes the rate of F activation and fusion 76
Structure-Guided Improvement of a Dual HPIV3/RSV Fusion Inhibitor 76
In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age 76
Single-chain variable fragment antibody constructs neutralize measles virus infection in vitro and in vivo 76
Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets 75
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure infection 75
Unity in diversity: shared mechanism of entry among paramyxoviruses 75
Inhibition of Nipah Virus Infection In Vivo: Targeting an early stage of paramyxovirus fusion activation during viral entry 75
Regulation of paramyxovirus fusion activation, the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state 74
Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds 73
Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery 73
Engineering Protease-Resistant Peptides to Inhibit Human Parainfluenza Viral Respiratory Infection 73
Human parainfluenza virus fusion complex glycoproteins imaged in action on authentic viral surfaces 72
Modulation of Oncogenic DBL Activity by Phosphoinositol Phosphate Binding to Pleckstrin Homology Domain 70
Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection 68
Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir) 68
Early Permissiveness of Central Nervous System Cells to Measles Virus Infection Is Determined by Hyperfusogenicity and Interferon Pressure 63
Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity 63
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern 63
How a paramyxovirus fusion/entry complex adapts to escape a neutralizing antibody 61
Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments 59
Human parainfluenza virus 3 field strains undergo extracellular fusion protein cleavage to activate entry 54
Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development 54
Subnanometer structure of an enveloped virus fusion complex on viral surface reveals new entry mechanisms 40
Host Cell Membrane Capture by the SARS-CoV-2 Spike Protein Fusion Intermediate 36
Totale 8.981
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.816
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021100 0 0 0 0 0 0 0 0 0 37 63 0
2021/2022461 6 1 5 66 159 4 5 11 14 1 33 156
2022/2023673 80 1 0 7 57 36 0 33 426 3 14 16
2023/2024350 25 5 10 4 142 64 1 3 1 2 14 79
2024/20251.493 23 100 4 10 192 196 89 102 168 418 110 81
2025/20265.211 242 319 258 366 379 2.812 170 344 246 75 0 0
Totale 8.981